P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE)

Kris Michael, M., Robert, B., Amer, B., Sridhar, C., Choquet, S., Dierickx, D., Rajani, D., Gamelin, L., Ghobadi, A., Norma, G.-B., Manher, J., Aditi, M., Sarah, N., Ran, R., Wei, Y., & Susan, P. (2023). P1390: NEW AND UPDATED RESULTS FROM A MULTICENTER OPEN-LABEL GLOBAL PHASE3 STUDY OF TAB-CEL FOR EBV+PTLD FOLLOWING HCT OR SOT AFTER FAILURE OF RITUXIMAB OR RITUXIMAB+CHEMOTHERAPY (ALLELE). HemaSphere, 7(S3), e0490265. https://doi.org/10.1097/01.hs9.0000972448.04902.65
Authors:
Mahadeo Kris Michael
Robert A. Baiocchi
Beitinjaneh Amer
Sridhar Chaganti
Sylvain Choquet
Daan Dierickx
D.C. Rajani
Laurence Gamelin
Armin Ghobadi
Guzman-Becerra Norma
Joshi Manher
Mehta Aditi
N Spisak Sarah
Reshef Ran
Wei Ye
Prockop Susan
Affiliated Authors:
Reshef Ran
Subjects:
Chimeric Antigen Receptor T Cell Therapy (OpenAlex Topic)
Epidemiology and Management of Cytomegalovirus Infection (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1097/01.hs9.0000972448.04902.65
DOI:
10.1097/01.hs9.0000972448.04902.65
Journal:
HemaSphere
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: